Colorectal cancer chemoprevention with aspirin

Gastrointestinal Oncology

Volumn 4, Issue 1, 2002, Pages 5-14

  Kune, Gabriel ^a  

^a NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADENOMA; ANGIOGENESIS; APOPTOSIS; CANCER RISK; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL CANCER; DRUG MECHANISM; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REVIEW;

EID: 0036510772     PISSN: 1475956X     EISSN: None     Source Type: Journal    
DOI: 10.1080/14759560290011262     Document Type: Review

References (90)

1. Acetylsalicylic acid, possible preventive of coronary thrombosis
2. Colorectal cancer risk, chronic illnesses, operations and medications: Case control results from the Melbourne colorectal cancer study
3. Chemoprevention of colorectal cancer
4. Use of non-steroidal anti-inflammatory drugs and incidence of colorectal cancer
5. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis
6. Chemopreventive activity of celecoxib, a specific cycloxygenase-2 inhibitor against colon carcinogenesis
7. Aspirin use and reduced risk of fatal colon cancer
8. A hypothesis: Non-steroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer
9. Aspirin use, cancer, and polyps of the large bowel
10. Aspirin and non-steroidal antiinflammatory drug (NSAID) use and risk of asymptomatic colorectal cancer: A case-control study of subjects participating in the Nottingham faecal occult blood (FOB) screening trial
11. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
12. Aspirin use and lung, colon, and breast cancer incidence in a prospective study
13. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer
14. Aspirin use and non-steroidal anti-inflammatory drug (NSAID) use and symptomatic colorectal cancer: A case-control study
15. Nonsteroidal antiinflammatory drugs and colorectal cancer
16. Aspirin and the risk of colorectal cancer in women
17. Nonsteroidal antiinflammatory drug use and protection against colorectal cancer in women
18. Aspirin and colorectal cancer
19. Nonsteroidal antinflammatory drug use and reduced risk of large bowel carcinoma
20. Regular aspirin use is associated with a protective effect for colorectal cancer
21. Aspirin use and chronic diseases: A cohort study of the elderly
22. Aspirin and colorectal cancer: The leisure World cohort revisited
23. Incidence of cancer among patients with rheumatoid arthritis
24. Low incidence of colorectal cancer in patients with rheumatoid arthritis
25. Decreased risk of colorectal cancer associated with peptic ulcer disease
26. Diseases preceding colon cancer. A case-control study among veterans
27. Relative risk of malignant tumors in analgesic abusers. Effects of long-term intake of aspirin
28. Aspirin use, cancer, and polyps of the large bowel
29. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: Case-control study of subjects participating in the Nottingham faecal occult blood screening programme
30. Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals
31. Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia
32. Risk factors for self-reported colon polyps
33. Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas
34. Reduced risk of large-bowel adenomas among aspirin users
35. Aspirin use and reduced occurrence of large bowel adenomas
36. Aspirin effects on large adenomas
37. Low-dose aspirin and incidence of colorectal tumors in a randomized trial
38. Low-dose aspirin and risk of developing colorectal polyps: The Physicians' Health Study
39. Aspirin use and colorectal cancer: Posttrial follow-up data from the Physicians' Health Study
40. Effect of aspirin on incidence and growth of aberrant crytpt foci induced in the rat colon by 12-dimethylhydrazine
41. Inhibition of aberrant crypt growth by non-steroidal antiinflammatory agents and differentiation agents in the rat colon
42. Aspirin, but not sodium salicylate, indomethacin, or nabumetone, reversibly suppresses 1,2-dimethylhydrazine-induced colonic aberrant crypt foci in rats
43. Aberrant crypt foci as biomarkers in chemoprevention for colorectal cancer
44. Chemopreventive effect of aspirin on growth of aberrant crypt foci in rats
45. Aspirin effect on distribution of aberrant crypt foci in human colons of patients with colorectal cancer
46. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin
47. Aspirin prevents tumors in a murine model of familial adenomatous polyposis
48. Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis
49. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds
50. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats
51. Aspirin reduces the incidence of colonic carcinoma in the dimethylhydrazine rat animal model
52. Inhibition of prostaglandin synthesis as mechanism of action for aspirin-like drugs
53. Effect of aspirin on prostaglandin E-2 formation and transforming growth factor alpha expression in human rectal mucosa from individuals with a history of adenomatous polyps of the colon
54. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas
55. Expression of prostaglandin synthase-1 and -2 protein in human colon cancer
56. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
57. Butyrate, aspirin and colorectal cancer
58. Aspirin and the potential role of prostaglandins in colon cancer
59. Altered eicosanoid levels in human colon cancer
60. Inhibition of human colon cancer cell growth by selective inhibition of cycloxygenase-2
61. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate
62. Effect of aspirin on cell proliferation and differentiation of colon adenocarcinoma Caco-2 cells
63. Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma
64. Inhibition of phenosulphotransferase by salicylic acid: A possible mechanism by which aspirin may reduce carcinogenesis
65. Nonsteroidal antiinflammatory drugs attenuate epidermal growth factor induced proliferation independent of prostaglandin synthesis inhibition
66. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis
67. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: Enhanced apoptosis in carcinoma and in in-vitro-transformed adenoma relative to adenoma cell lines
68. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: Effects on cell cycle and apoptosis
69. Effect of aspirin in induction of apoptosis in HT-29 human colon adenocarcinoma cells
70. Non-steroidal antiinflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis
71. Alterations in cellular adhesion and apoptosis in epithelial cells over-expressing prostaglandin endoperoxide synthase-2
72. Effects of nonsteroidal antiinflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway
73. Inhibition of the growth of 12V-ras-transformed rat fibroblast by acetysalicylic acid correlates with inhibition of NF-kappa B
74. Sodium salicylate induces apoptosis via p38 nitrogen-activated protein kinase but inhibits tumor necrosis factor-induced C-jun N-terminal kinase/stress-activated protein kinase activation
75. Aspirin and salicylate induce apoptosis and activation of caspases in-cell chronic Imphatic leukemia cells
76. Cyclooxygenase regulates angiogenesis induced colon cancer cells
77. A review of mechanism of action of aspirin and its potential as an immunomodulating agent
78. Recovery from 4-(methylnitrosamine)-1-(3-puridyl)-1-butanone-induced immunosuppression in A/J mice by treatment with nonsteroidal antiinflammatory drugs
79. Suppression of human colorectal mucosal prostaglandins: Determining the lowest effective aspirin dose
80. Chemoprevention of colorectal cancer by aspirin: A decision analysis
81. Aspirin and other platelet-active drugs. The relationship among dose, effectiveness and side effects
82. Final report on the aspirin component of the ongoing physicians' study
83. Risk of gastrointestinal haemorrhage with long term use of aspirin: Meta-analysis
84. Aspirin as prophylactic against colorectal cancer
85. Nonsteroidal antiinflammatory drugs as anticancer agents: Mechanistic, pharmacologic and clinical issues